FN Media Group Presents Safehaven.com Market Commentary
New York, NY – January 20, 2021 – On October 10, 1962, JFK signed into law a little-known act that helped put a massive $1.25 trillion industry on the map. And today, the trillion-dollar pharmaceutical industry is being pushed to make a shift. Mentioned in today’s commentary includes: AbbVie Inc. (NYSE: ABBV), NewAge, Inc. (NASDAQ: NBEV), The Scotts Miracle-Gro Company (NYSE: SMG), Aphria Inc. (NASDAQ: APHA), The Green Organic Dutchman Holdings Ltd. (OTCQX: TGODF).
This is a new way to create safe, proven treatments while saving companies significant amounts of money…Treatments that could help ease common ailments that plague millions of folks each year like chronic pain, inflammation, migraines, and more.
It could have tremendous implications for the future of the biotech market. That’s because the 1962 Kefauver Harris Amendment helped make sure the medications we take are both safe and effective…But that often came with long, arduous review processes that left desperate people waiting years for relief.
In 2020, however, we’ve seen a massive shift take place in the biotech industry thanks to the fast-tracked COVID vaccine…Proving that with today’s technology, it’s finally possible to cut through the red tape in the process…Delivering the potential to produce treatments and vaccines that are both safe and effective at record speeds. And now, the next possible breakthrough in health sciences is in the perfect position to capitalize on that in 2021 and the little known company at the forefront is called Juva Life (JUVA; JUVAF).
Many of the companies in this market are seeing incredible gains this year.
Harborside, Inc., a San Francisco-based dispensary operator, saw shares soar 423% in just 9 months. Indus Holdings, another manufacturer and distributor in the Bay Area, launched for extraordinary 528% gains in 2020. But some investors are keeping their eyes on another young company near San Francisco that has big plans in store.
In December, their shares were up an impressive 44% in just three weeks. But with a target to do things differently, they have even greater plans in the months to come.
Juva Life (JUVA; JUVAF) aims to have a large database for evidence-based cannabis treatments…And they’ll soon have the facilities to take that valuable data proving what works best and for who…And turn it into an asset that could potentially make them an instant acquisition target.
A New Path for Safe, Effective Treatments
The start of this massive boom began in California, when they legalized medical marijuana with overwhelming support in 1996. Since then, dozens of other states and entire nations have jumped onboard…And the global cannabis industry is expected to reach an incredible $57 billion by 2025.
That’s helping to ease the suffering of countless people around the world struggling with conditions from migraines and chronic pain to cancer.In fact, in a breakthrough study, 92% of patients said that medical marijuana was helpful in alleviating their symptoms. But in this booming industry, there’s been one huge problem.
With federal laws still classifying medical marijuana as a Schedule I drug, it’s stifled their ability to conduct the studies proving the incredible effects that individuals have been reporting for years. That’s why Juva Life (JUVA; JUVAF) has aimed to create a very detailed database, unlocking a whole new world of opportunities. It’s expected to be the first major database compiling data for proven, effective treatments in this long-overlooked area.
So rather than going through a process that can cost up to $2.6 billion to develop a new treatment through the FDA…And can take up to a decade of time…Juva Life will use an IRB-approved process that could lead to effective treatments with just a fraction of the cost and time.
But the most exciting part is that after they’ve compiled the data…Juva Life plans to use artificial intelligence (AI), proprietary software, and their team’s collective decades of experience to create proprietary versions of the most effective, proven treatments.
Already Driving Revenue – And the Pace is Picking Up
While it usually costs over $2 billion to develop new treatments the old way through the FDA…They are aiming to cut years, billions of dollars, and lots of risk out of the process because of the IRB-approved processes they can conduct their research through.
Juva Life has pinpointed what they see as strategic holes in the market all around the San Francisco area, including retail and delivery services. And they opened operations in Redwood City and Stockton in 2020
They’ve been delivering the best, most trusted products to the area for several months already…But soon, they plan on creating and distributing their own in-house brands.
They’ve already received local approval to open their production facility shortly, and they’re expected to be producing their own products within 6-8 months. The revenue Juva Life has already been able to drive from a secondary asset is important. Particularly during a year when many businesses have been shuttered due to the pandemic and government shutdowns.
In the coming weeks, they hope to have the new database off the ground, then later enrolling patients in the studies that could modernize parts of the biotech industry. At the same time, they’re expected to begin cultivating their own products which could soon become the most trusted, evidence-based brand on the markets.
And with Juva Life (JUVA; JUVAF) pioneering a model that could save the big players piles of cash in the drug development process, if it works as planned this could make draw major attention as a potential acquisition target in the near future. It’s an opportunity that could disrupt a part of the entire industry.
The Cannabis Boom Is Drawing In Many Different Industries
AbbVie Inc (NYSE:ABBV) is first and foremost a research-based biopharmaceutical company. Its team of top scientists focus on technology and innovation to create sustainable growth and address some of the world’s biggest medical dilemmas.
So what does AbbVie have to do with cannabis? A lot, in fact. AbbVie is one of the pioneers of marijuana-based treatment in the biopharmaceutical industry, realizing the potential of its once-cornerstone product, Marinol, years ahead of the competition.
While the drug had a good run with AbbVie, the company offloaded its rights to Marinol to Alken Labs for $10 million in 2019. In the more recent months, AbbVie has shifted its focus to technology and hardware, inking a deal in early January to acquire Allergan Aesthetics.
NewAge Inc. (NASDAQ:NBEV) is a Colorado-based company with a focus on all things health and wellness. While it had a strong run as a CBD beverage company, it recently underwent a makeover, changing its name to reflect its growing range of wellness products. And though CBD beverages and beauty products still represent a significant portion of its sales, the decision to branch out was obvious considering how quickly the health and wellness market is growing, and how intertwined the two industries are.
NewAge is one of the few companies in this industry that emerged from 2020 even stronger than it began. And this year may even be better. Since the first day of trading in 2021, NewAge has already seen its stock price jump by 15%, and it’s just getting started.
The Scotts Miracle-Gro Company (NYSE:SMG) is a rather unique way to play the cannabis boom. While the connection may be obvious to some, it’s not widely recognized its role in the industry. Scotts is a household name for many thanks to its lawn care brands, Miracle Gro and its Round Up pesticide, but it has been quietly expanding into the marijuana scene for some time with a series of hydroponic developments and acquisitions. And it’s easy to see why.
Scotts has a pretty strong stance on marijuana legalization. On the company’s website, it explains, “Congress should honor the principles of federalism and states’ rights by passing legislation that respects the will of voters and state legislatures that have elected to adopt their own approach to authorizing the use of cannabis within their boundaries.”
Scotts is looking to take advantage of this in a big way. In fact, its hydroponics sales topped $700 million last year, and as the legalization push continues to grow, so too will its sales. Thanks to its approach to the industry, Scotts has drastically outperformed the wider weed market, and was practically unfazed by the COVID-sparked market downturn in 2020.
Aphria Inc (NASDAQ:APHA), currently valued at just over $3.5 billion, is a giant in the industry. The Ontario-based cannabis company has operations in more than 10 countries and distributes medical cannabis across the globe. Thanks to its big-picture approach to the industry, Aphria has been able to thrive while many of its peers have stumbled.
Recently, in anticipation of wider U.S. legalization, Aphria entered into a $300 million deal to acquire SweetWater Brewing, one of the biggest craft beer brewers in the United States. The purchase aims to help Aphria capitalize on the growing “lifestyle” market associated with both craft beer and high-end cannabis.
Aphria Chairman and CEO Irwin Simon noted, “We will establish and grow our U.S. presence through SweetWater’s robust, profitable platform of craft brewing innovation, manufacturing, marketing and distribution expertise.”
The Green Organic Dutchman (OTCQX:TGODF) is primarily a research and development company focusing on cannabinoid-based products. Most of its products are dried organic cannabis, oils and edibles, but it also is involved in breeding plants to create new strains and distributing seeds for medical applications.
Recently, the Canada-based Dutchman announced that it has been approved to export medical cannabis to Europe. Sean Bovingdon, Interim CEO of TGOD, commented, “This is an important milestone as we get ready to begin the international shipping of our certified organically grown medical cannabis products.”
The Green Organic Dutchman had a rough first half of 2020 like most of its competition, shedding over half of its market cap from January to April. Since then, however, the Dutchman has staged somewhat of a comeback, especially since the beginning of this year. Since January 4th, the Dutchman has seen its share price climb by 42%, and this is just the beginning.
By. Zara Newman
**IMPORTANT! BY READING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY**
Certain statements in this press release are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the results expressed or implied by the forward-looking statements. Such forward-looking information includes that cannabis use and sales will grow as currently predicted; timing of Juva’s construction or acquisition of facilities and commencement of associated additional revenues; that Juva will be granted patents for its specific formulations; that cannabis patents and proprietary databases will prove valuable assets; Juva’s intended expansion into more markets; Juva’s plans to bring the latest science and technology to its product research and development; that it could be granted growing and sales licenses; that Juva can lease new sales locations and gain brand recognition; that through efficiency and vertical integration Juva can substantially lower its production costs and time of product development below competitors; that Juva can sell its product profitably; that Juva will create a range of cannabis consumer healthcare products, to be distributed through their own distribution channels; that Juva can successfully integrate pharmaceutical breakthroughs into its products; that Juva can achieve its sales targets and gross profit margins as planned; and that it will be able to carry out its business plans.
Readers are cautioned to not place undue reliance on forward-looking information. Forward looking information is subject to risks and uncertainties which include, among other things: that regulatory approvals may not be obtained or may be obtained subject to conditions that are not anticipated; growing competition in the cannabis industry; announced or expected business plans may not come to fruition because of inability to come to final terms, or inability to obtain regulatory compliance; competitors may quickly enter the industry; general economic conditions in the US, Canada and globally; the inability to secure financing necessary to carry out its business plans; competition for, among other things, capital and skilled personnel; the possibility that government policies or laws may not permit legal cannabis sales or growth or that favorable laws in place may change; interruption or failure of information or other technology systems; the cannabis market may not grow as expected; Juva’s drive for efficiency, time and cost savings may not achieve the expected results and its accomplishments may be limited; Juva may not successfully develop a cannabis consumer brand; and it may not be successful in developing a cannabis based treatment for medical uses; even if it develops successful healthcare treatments, the products may not be accepted by the market; the company may not be able to protect its intellectual property; its patent applications may be rejected or successfully challenged; Juva’s business plan carries risk, including its ability to comply with all applicable governmental regulations in a highly regulated business; early entry risk by engaging in activities currently considered illegal under US federal laws; and regulatory risks relating to Juva’s business, financings and strategic acquisitions.
PAID ADVERTISEMENT. This communication is a paid advertisement and is not a recommendation to buy or sell securities. Safehaven.com, owned by Medtronics Online Solutions Ltd., and their owners, managers, employees, and assigns (collectively “Safehaven.com”) have been paid by the profiled company to disseminate this communication. In this case Safehaven.com has been paid by Juva ninety thousand US dollars for this article and certain banner ads. This compensation is a major conflict with our ability to be unbiased, more specifically:
This communication should be viewed as a commercial advertisement only. We have not investigated the background of the company. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor awareness marketing, which often end as soon as the investor awareness marketing ceases. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters.
SHARE OWNERSHIP. The owner of Safehaven.com owns shares of Juva and therefore benefits from its price appreciation. Safehaven.com will not notify the market when it decides to buy or sell shares of this issuer in the market. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.
NOT AN INVESTMENT ADVISOR. Safehaven.com is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.
DISCLAIMER: Safehaven.com is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with Safehaven.com or any company mentioned herein. The commentary, views and opinions expressed in this release by Safehaven.com are solely those of Safehaven.com and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.
FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact – FN Media Group LLC